Last updated: September 28, 2026
Accolate, the brand name for zafirlukast, is a mature leukotriene-receptor antagonist with limited commercial relevance in the United States. AstraZeneca commercialized the product after its 1996 FDA approval, but montelukast, inhaled corticosteroids, combination inhalers and generic competition reduced its market position. Accolate has no meaningful current exclusivity, no biosimilar pathway, and no publicly reported standalone revenue. Its remaining value is concentrated in generic supply, selected international markets and the broader leukotriene-modifier segment rather than in the branded product.
What is Accolate and how is zafirlukast used?
Accolate is an oral asthma-control medicine containing zafirlukast. It blocks cysteinyl leukotriene receptors and is indicated for the prophylaxis and chronic treatment of asthma in adults and children aged five years and older. It is not intended for the immediate reversal of acute bronchospasm. The approved strengths are 10 mg and 20 mg tablets. [1]
| Product attribute |
Accolate and zafirlukast |
| Active ingredient |
Zafirlukast |
| Drug class |
Leukotriene-receptor antagonist |
| Dosage form |
Oral tablet |
| U.S. strengths |
10 mg and 20 mg |
| Original U.S. sponsor |
AstraZeneca predecessor companies |
| FDA approval |
1996 |
| Primary indication |
Chronic asthma control |
| Acute rescue use |
No |
| Biologic status |
No; small-molecule drug |
| Current commercial profile |
Mature, largely generic market |
| Standalone revenue disclosure |
Not reported by AstraZeneca |
The product’s clinical positioning was strongest among patients seeking an oral alternative or adjunct to inhaled asthma therapy. Its commercial limitations included twice-daily dosing, liver-related safety monitoring concerns, drug interactions and the superior market penetration of montelukast.
When did Accolate lose exclusivity?
Accolate lost practical market exclusivity after the expiration of its core patent protection and the subsequent entry of generic zafirlukast. The precise commercial erosion occurred over a longer period than a single legal expiry date because branded prescription volume declined as competing asthma medicines gained share.
The key exclusivity milestones are:
| Milestone |
Date or period |
Commercial effect |
| FDA approval of Accolate |
1996 |
Established the branded U.S. product |
| Montelukast approval |
1998 |
Introduced a stronger once-daily leukotriene competitor |
| Generic zafirlukast development |
Late 1990s and 2000s |
Increased price pressure |
| Core patent expiry period |
Primarily 2000s to early 2010s |
Removed effective branded protection |
| U.S. branded decline |
2000s onward |
Reduced Accolate’s prescription and revenue base |
| Current status |
Mature generic market |
No material brand premium |
A single “loss of exclusivity” date does not capture the product’s financial trajectory. Accolate’s competitive position had already weakened substantially before the end of its commercial life because physicians increasingly favored montelukast and inhaled controller therapies.
What patents protected Accolate and zafirlukast?
The original zafirlukast patent estate covered the active compound and related leukotriene-antagonist chemistry. The relevant U.S. patent protection expired years ago, and no active Orange Book patent is expected to block ordinary generic zafirlukast entry.
Patent protection for a small-molecule product typically includes several layers:
- Composition-of-matter claims covering zafirlukast or related chemical entities.
- Pharmaceutical-composition claims covering tablets and excipients.
- Process claims covering synthesis or purification.
- Method-of-use claims covering treatment or prevention of asthma.
The commercial importance of the composition patent was highest because it could block any generic containing the same active ingredient. Formulation and manufacturing patents would have been narrower and easier to design around.
What is the Orange Book status of Accolate?
The FDA Orange Book remains the relevant U.S. source for determining listed patents, exclusivity and approved reference-product status. Accolate’s historical NDA is associated with zafirlukast tablets, while generic products are associated with abbreviated new drug applications. The product has no current new-chemical-entity exclusivity and no meaningful remaining patent barrier to generic competition. [2]
The Orange Book does not establish commercial availability. A product can remain listed in FDA records while the branded product is no longer actively marketed or while generic supply is intermittent.
Were there Paragraph IV challenges to Accolate?
Generic manufacturers could challenge listed patents through an abbreviated new drug application and a Paragraph IV certification. Paragraph IV litigation was commercially relevant during the period when AstraZeneca or its predecessors maintained enforceable listed patents.
Publicly available FDA records establish the generic pathway but do not provide a complete economic history of every zafirlukast Paragraph IV filing. The later commercial outcome is clear: generic zafirlukast became available, and the branded product no longer commands meaningful exclusivity.
The likely launch sequence for a generic challenger would have been:
- ANDA filing with a Paragraph IV certification against any unexpired listed patent.
- Patent litigation or a settlement agreement if the sponsor sued within the Hatch-Waxman statutory period.
- A 30-month stay if statutory conditions were met.
- Generic launch after patent invalidation, non-infringement, patent expiry or settlement-based entry.
- Rapid price erosion after multiple suppliers entered.
There is no current business case for a new Paragraph IV campaign against Accolate. The product is too mature, and any remaining opportunity is more likely to involve manufacturing efficiency, supply reliability or niche distribution.
What was Accolate’s financial trajectory?
AstraZeneca did not separately disclose Accolate revenue in its public annual reports. The product was reported within broader respiratory or established-product portfolios. As a result, no reliable public series shows annual Accolate sales, operating profit or cash flow.
The financial trajectory can be divided into four phases:
Launch and early adoption
Following its 1996 approval, Accolate entered the growing asthma-controller market. Oral administration gave it a potential adherence and convenience advantage over inhaled medicines. Its commercial opportunity was meaningful but constrained by the established role of inhaled corticosteroids.
Competitive displacement
Montelukast, marketed as Singulair, became the dominant leukotriene-modifier product. Once-daily dosing, broad physician adoption and strong commercial promotion supported montelukast’s expansion. Singulair’s success reduced the addressable market for Accolate and limited its pricing power.
Generic erosion
Generic zafirlukast reduced the economic value of the brand. In mature small-molecule markets, price competition usually begins with the first generic entrant and intensifies as additional suppliers qualify. Pharmacy substitution then shifts volume away from the branded product.
Post-brand residual market
Accolate’s remaining value is low. Any residual sales depend on legacy prescribing, payer coverage, patient response, formulary placement and generic supply conditions. AstraZeneca’s financial reports do not identify Accolate as a material contributor to consolidated revenue. [3]
| Financial indicator |
Publicly supportable conclusion |
| Historical brand revenue |
Not separately disclosed |
| Current brand revenue |
Not publicly reported as material |
| Generic market value |
Fragmented and price-sensitive |
| Royalty stream |
No material publicly identified royalty stream |
| Major growth driver |
None apparent |
| Main financial risk |
Further substitution and discontinuation |
| Residual opportunity |
Niche generic supply and selected foreign markets |
How does Accolate compare with Singulair and inhaled asthma therapies?
Accolate was commercially disadvantaged by both drug-class competition and treatment-guideline preferences.
| Factor |
Accolate |
Singulair |
Inhaled corticosteroids |
| Active ingredient |
Zafirlukast |
Montelukast |
Various |
| Administration |
Oral |
Oral |
Inhaled |
| Historical dosing |
Twice daily |
Once daily |
Product-dependent |
| Role |
Controller or adjunct |
Controller or adjunct |
Core controller therapy |
| Brand strength |
Limited |
Historically strong |
Distributed across many brands |
| Generic pressure |
High |
High after patent expiry |
High in mature products |
| Current commercial position |
Low |
Mature but larger historical base |
Large therapeutic category |
| Acute rescue use |
No |
No |
No |
Montelukast had the stronger commercial profile because it combined oral dosing with once-daily administration. Inhaled corticosteroids remained central to asthma management because they directly address airway inflammation and are supported by treatment guidelines. Leukotriene antagonists were generally used as alternatives or add-on treatments rather than as the dominant controller class.
What generic entry risks exist for Accolate?
Generic entry risk is effectively realized rather than prospective. The principal risks are no longer patent-driven. They are commercial and operational:
- Multiple approved suppliers can compress prices.
- Low-volume products can face manufacturing discontinuation.
- Supply interruptions can cause temporary price increases without restoring durable brand value.
- Payers can prefer other generic leukotriene modifiers.
- Physicians can switch patients to montelukast or inhaled therapies.
- Limited demand can reduce distributor inventory and pharmacy availability.
A generic manufacturer considering zafirlukast would need to assess market size, active supplier count, API availability, bioequivalence requirements, tablet manufacturing economics and the likelihood of FDA-approved competitors remaining commercially active.
What formulation patents protect zafirlukast?
No current formulation patent appears to create a commercially significant barrier to ordinary zafirlukast tablets. The product is a conventional immediate-release tablet rather than a complex injectable, inhaled device or long-acting delivery system.
Potential formulation issues include:
- Tablet dissolution and bioequivalence.
- Stability of the active pharmaceutical ingredient.
- Excipients and compression characteristics.
- Packaging and shelf-life requirements.
- Control of impurities and degradation products.
These factors can create regulatory and manufacturing work, but they do not normally support durable brand exclusivity after the core composition patent has expired.
Is there biosimilar risk for Accolate?
Accolate has no biosimilar risk because zafirlukast is a synthetic small molecule, not a biologic. The relevant competitive pathway is the FDA ANDA process for generic drugs. Biosimilar regulation under the Public Health Service Act does not apply.
The distinction matters commercially. Generic entrants can obtain approval by demonstrating pharmaceutical equivalence and bioequivalence to the reference product. They do not need to reproduce a biologic manufacturing process or establish biosimilarity.
What patent litigation and settlement agreements affect Accolate?
No current high-value patent litigation appears to affect Accolate. The product’s key U.S. patent protections expired long ago, and the commercial market is mature.
Historical Hatch-Waxman disputes may have influenced the timing of generic entry, but those disputes no longer determine market access. Any settlement involving early generic entry would now be commercially historical rather than an active constraint on launch.
The absence of current litigation does not imply that every historical patent dispute was immaterial. It means the litigation risk has ceased to be the principal determinant of product value.
Which companies compete with Accolate?
Competition operates at three levels:
Leukotriene modifiers
Montelukast is the principal historical comparator. Generic montelukast has a much stronger prescribing base and broader physician familiarity. Zileuton represents another leukotriene-pathway drug but has a narrower commercial role and additional monitoring considerations.
Inhaled controller products
Inhaled corticosteroids, inhaled corticosteroid and long-acting beta-agonist combinations, and other inhaled therapies compete for the same asthma-control budget. These products often have stronger guideline positioning than oral leukotriene antagonists.
Generic manufacturers
Generic zafirlukast suppliers compete on price, supply reliability, wholesaler access and formulary status. The market is unlikely to support significant promotional spending because the product is mature and clinically substitutable.
What is the geographic coverage of Accolate?
The commercial footprint is uneven. U.S. branded relevance is limited, while zafirlukast may continue to appear in selected international markets through generic or legacy products. Marketing authorization, active supply and brand ownership vary by jurisdiction.
A global assessment must separate:
- Regulatory approval from active commercialization.
- Brand ownership from local distributor rights.
- Patent expiry from market availability.
- Listed products from products with current sales.
- Generic registration from actual pharmacy supply.
AstraZeneca’s global reporting does not identify Accolate as a material international growth product. Any residual geographic value is likely to be country-specific and dependent on local generic competition.
How strong is the Accolate patent estate?
The current patent estate is weak from an investment or licensing perspective. Its principal strengths were historical:
- Early composition protection.
- Regulatory approval for chronic asthma.
- Established clinical identity.
- Existing manufacturing and regulatory history.
Its current weaknesses are more important:
- Core patent protection has expired.
- No current exclusivity protects the brand.
- The product competes with lower-cost generics.
- Montelukast has stronger historical market recognition.
- Inhaled therapies occupy the central treatment position.
- AstraZeneca does not report Accolate as a material revenue contributor.
What is the outlook for Accolate revenue?
The outlook is flat to declining for the branded product and low for the overall molecule. Revenue growth would require an unusual event, such as a supply disruption affecting alternatives, a new commercial agreement in an underserved market or renewed clinical interest in oral leukotriene therapy. None is evident in the public regulatory and corporate record.
The more probable scenarios are:
| Scenario |
Probability profile |
Commercial result |
| Continued generic availability |
Most likely |
Low, stable molecule-level sales |
| Brand re-launch |
Unlikely |
Limited return because of generic substitution |
| Generic consolidation |
Possible |
Higher unit prices but lower volume |
| Permanent market withdrawal |
Possible in some countries |
Reduced access and negligible sales |
| New patent-driven lifecycle strategy |
Highly unlikely |
No evident legal basis |
Key Takeaways
- Accolate is the branded form of zafirlukast, an oral leukotriene-receptor antagonist approved by the FDA in 1996.
- Its commercial decline resulted from montelukast, inhaled asthma therapies and generic substitution.
- AstraZeneca has not publicly disclosed standalone Accolate revenue.
- The product has no remaining meaningful U.S. exclusivity.
- Generic zafirlukast, not biosimilar competition, is the relevant market pathway.
- Current patent and litigation risks are low because the core protection has expired.
- The product’s residual value is limited to generic supply, niche prescribing and selected international markets.
- Accolate is not a material growth asset for AstraZeneca or a strong candidate for branded relaunch.
FAQs
Is Accolate still sold in the United States?
Accolate has little or no meaningful branded U.S. commercial presence. Zafirlukast may remain available through generic channels, subject to supplier and pharmacy inventory.
Can a company launch a generic version of Accolate?
Yes. The relevant route is an FDA ANDA supported by pharmaceutical equivalence and bioequivalence. Expired patent protection does not prevent ordinary generic entry.
Did AstraZeneca discontinue Accolate?
AstraZeneca no longer treats Accolate as a material commercial product in its public financial reporting. Product availability may differ by country and distributor.
Is zafirlukast a substitute for montelukast?
Both are leukotriene-receptor antagonists used in asthma management, but montelukast has historically had stronger commercial adoption and once-daily dosing. Treatment selection depends on the patient and prescriber.
Does Accolate have orphan-drug or pediatric exclusivity?
Accolate is not generally associated with current orphan-drug exclusivity. Any historical pediatric or regulatory exclusivity would have expired and would not block present generic competition.
References
-
U.S. Food and Drug Administration. (1996). Accolate (zafirlukast) prescribing information. FDA Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
AstraZeneca PLC. (1996-2024). Annual reports and financial statements. https://www.astrazeneca.com/investor-relations/annual-reports.html
